Suppr超能文献

肾上腺素能成分和心脏肥大细胞脱颗粒在预处理诱导的心脏保护中的可能作用。

Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection.

作者信息

Parikh V, Singh M

机构信息

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

出版信息

Pharmacol Res. 1999 Aug;40(2):129-37. doi: 10.1006/phrs.1999.0501.

Abstract

The present study was designed to investigate the role of adrenergic component and cardiac mast cell degranulation in the cardioprotective effect of ischaemic preconditioning. Isolated rat hearts were subjected to 30 min of global ischaemia followed by 30 min of reperfusion. Ischaemic/norepinephrine (100 microm) preconditioning markedly reduced ischaemia-reperfusion-induced release of lactate dehydrogenase (LDH) and creatine kinase (CK) in coronary effluent and the incidence of ventricular premature beats (VPBs) and ventricular tachycardia/fibrillation (VT/VF) during the reperfusion phase. Moreover, ischaemic/norepinephrine preconditioning significantly reduced ischaemia-reperfusion-induced release of mast cell peroxidase (MPO), a marker of mast cell degranulation. Prazosin (0.1 microm), a alpha(1)adrenoceptor blocker, administered during ischaemic/norepinephrine preconditioning attenuated the cardioprotective and antiarrhythmic effect of ischaemic/norepinephrine preconditioning. MPO release increased immediately after ischaemic/norepinephrine preconditioning and the release was found to be inhibited in hearts subjected to ischaemic/norepinephrine preconditioning in the presence of prazosin. However, prazosin (0.1 microm) treatment per se produced cardioprotective and antiarrhythmic effects and reduced ischaemia-reperfusion-induced MPO release. These findings tentatively suggest that ischaemic preconditioning produced cardioprotective and antiarrhythmic effect by activating alpha(1)adrenoceptors and consequent degranulation of cardiac mast cells. Prazosin administered during ischaemic preconditioning abolished its ameliorative effect.

摘要

本研究旨在探讨肾上腺素能成分和心脏肥大细胞脱颗粒在缺血预处理心脏保护作用中的作用。将离体大鼠心脏进行30分钟全心缺血,随后再灌注30分钟。缺血/去甲肾上腺素(100微摩尔)预处理显著降低了缺血再灌注诱导的冠状动脉流出液中乳酸脱氢酶(LDH)和肌酸激酶(CK)的释放,以及再灌注期室性早搏(VPB)和室性心动过速/心室颤动(VT/VF)的发生率。此外,缺血/去甲肾上腺素预处理显著降低了缺血再灌注诱导的肥大细胞过氧化物酶(MPO)的释放,MPO是肥大细胞脱颗粒的标志物。在缺血/去甲肾上腺素预处理期间给予哌唑嗪(0.1微摩尔),一种α(1)肾上腺素能受体阻滞剂,减弱了缺血/去甲肾上腺素预处理的心脏保护和抗心律失常作用。缺血/去甲肾上腺素预处理后MPO释放立即增加,并且发现在存在哌唑嗪的情况下,接受缺血/去甲肾上腺素预处理的心脏中MPO释放受到抑制。然而,哌唑嗪(0.1微摩尔)治疗本身产生了心脏保护和抗心律失常作用,并减少了缺血再灌注诱导的MPO释放。这些发现初步表明,缺血预处理通过激活α(1)肾上腺素能受体以及随后的心脏肥大细胞脱颗粒产生心脏保护和抗心律失常作用。在缺血预处理期间给予哌唑嗪消除了其改善作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验